Erwin De Genst

Erwin De Genst

Auto-generated profile, based on publicly available information

Erwin De Genst

Biologics Engineering, Oncology R&D, AstraZeneca , Cambridge,CB2 0AA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2017 in BMC Biology
Verified
Journal Article
Open access
PDF file
MIMarija Iljina
Marija Iljina
LHLiu Hong
Liu Hong
MHMathew Horrocks
Mathew Horrocks
MLMarthe H. Ludtmann
Marthe H. Ludtmann
MCMinee L. Choi
Minee L. Choi
DKDavid Klenerman
David Klenerman
The aggregation of the protein ɑ-synuclein (ɑS) underlies a range of increasingly common neurodegenerative disorders including Parkinson’s disease. One widely explored therapeutic strategy for these conditions is the use of antibodies to target aggregated ɑS, although a detailed molecular-level mechanism of the action of such species remains elusive. Here, we characterize ɑS aggregation in vitro in the presence of two ɑS-specific single-domain antibodies (nanobodies), NbSyn2 and NbSyn87, which bind to the highly accessible C-terminal region of ɑS. We show that both nanobodies inhibit the formation of ɑS fibrils. Furthermore, using single-molecule fluorescence techniques, we demonstrate that nanobody binding promotes a rapid conformational conversion from more stable oligomers to less stable oligomers of ɑS, leading to a dramatic reduction in oligomer-induced cellular toxicity. The results indicate a novel mechanism by which diseases associated with protein aggregation can be inhibited, and suggest that NbSyn2 and NbSyn87 could have significant therapeutic potential.

31 May 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
EGErwin De Genst
Erwin De Genst
KFKylie S. Foo
Kylie S. Foo
YXYao Xiao
Yao Xiao
EREduarde Rohner
Eduarde Rohner
EVEmma de Vries
Emma de Vries
KCKenneth R. Chien
Kenneth R. Chien
The dysregulated physical interaction between two intracellular membrane proteins, the sarco/endoplasmic reticulum Ca2+ ATPase and its reversible inhibitor phospholamban, induces heart failure by inhibiting calcium cycling. While phospholamban is a bona-fide therapeutic target, approaches to selectively inhibit this protein remain elusive. Here, we report the in vivo application of intracellular acting antibodies (intrabodies), derived from the variable domain of camelid heavy-chain antibodies, to modulate the function of phospholamban. Using a synthetic VHH phage-display library, we identify intrabodies with high affinity and specificity for different conformational states of phospholamban. Rapid phenotypic screening, via modified mRNA transfection of primary cells and tissue, efficiently identifies the intrabody with most desirable features. Adeno-associated virus mediated delivery of this intrabody results in improvement of cardiac performance in a murine heart failure model. Our strategy for generating intrabodies to investigate cardiac disease combined with modified mRNA and adeno-associated virus screening could reveal unique future therapeutic opportunities.

7 September 2017 in Biomacromolecules
Verified
Journal Article
Closed access
USUlyana Shimanovich
Ulyana Shimanovich
TMThomas C.T. Michaels
Thomas C.T. Michaels
EGErwin De Genst
Erwin De Genst
DMDijana Matak-Vinkovic
Dijana Matak-Vinkovic
CDChristopher M. Dobson
Christopher M. Dobson
Tuomas KnowlesTuomas Knowles
Tuomas Knowles

15 October 2026 in Nucleic Acids Research
Verified
Journal Article
Open access
CGClare M C Gillis
Clare M C Gillis
KBKlara Kropivšek Brumat
Klara Kropivšek Brumat
AMArio de Marco
Ario de Marco
OOOlga Obrezanova
Olga Obrezanova
EGErwin De Genst
Erwin De Genst
MRMatthew I J Raybould
Matthew I J Raybould
VHHs, the variable regions of camelid heavy-chain antibodies, are increasingly used as therapeutic, diagnostic, and research tools because of their small size and stability. Despite the growing number of publicly available VHH repertoire sequencing studies, there is no large-scale, web-accessible database of VHH sequences. Here, we present OAS-nano, a database containing over 73 million unique VHH sequences collected from 16 public repertoire sequencing datasets and 1 previously unpublished dataset, spanning alpaca, llama, and Bactrian camel repertoires. Sequence reads were processed using a standardized pipeline to extract high-quality VHH sequences. Experimental metadata and sequence annotations enable users to identify sequences appropriate for their use case. OAS-nano is freely available at https://oas-nano.opig.stats.ox.ac.uk/.